Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

Sponsor

Organon and Co (Industry)

Overall Status

Completed

CT.gov ID

NCT00702806

Collaborator

(none)

Enrollment

Arms

15.5

Actual Duration (Months)

Study Details

Study Description

Brief Summary

The primary objective of this trial was to investigate the appropriate dose of a single injection of Org 36286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH) protocol for IVF and IVF/ICSI. After seven days, participants were converted to treatment with Puregon® 150 IU and administration of the GnRH antagonist Orgalutran® to finalize the stimulation cycle. Secondary objectives were the safety (including the absence of antibody formation) and the direct effects of Org 36286 on reproductive functions (steroidogenesis, oocyte maturation, embryo quality and implantation).

Condition or Disease	Intervention/Treatment	Phase
Infertility In Vitro Fertilization	Drug: Org 36286 Drug: Puregon® Drug: Orgalutran® Drug: Pregnyl®	Phase 2

Detailed Description

This trial was made up of two stages with different designs and was conducted at two clinical trial sites. Stage I was open-label and uncontrolled in a small cohort of women (n=6) to obtain first experience in employing Org 36286 in women meeting all inclusion and none of the exclusion criteria. Based on the results of a previous study, the most appropriate dose was anticipated to be 120 μg Org 36286, which was administered on Cycle Day 2 or 3. After seven days, treatment was continued with a fixed dose of 150 IU Puregon® SC. If the size of the leading follicle was >=14 mm, 0.25 mg Orgalutran® SC once daily was administered concurrently with 150 IU Puregon® up to and including the day of hCG. The maximum total treatment duration was 19 days. Treatment of the first two participants with Org 36286 120 μg, that was expected to be adequate for COH, was cancelled due to disrupted follicular growth beyond Day 7. Therefore, the dose of Org 36286 was adapted from 120 μg to 180 µg. Treatment of the first participants gave an indication of the validity of the anticipated doses to be used in Stage II, the actual dose-finding trial. Stage II was open-label, prospective and randomized, comparing three experimental regimens differing in dose of Org 36286 (120 μg, 180 μg, or 240 μg) with a reference treatment. Post-treatment assessments were completed at the visit two weeks after embryo transfer.

Study Design

Study Type:

Interventional

Actual Enrollment :

99 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II, Open Label, Prospective, Randomized, Comparative Clinical Trial to Investigate the Appropriate Dose of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI.

Actual Study Start Date :

Jul 1, 2001

Actual Primary Completion Date :

Oct 15, 2002

Actual Study Completion Date :

Oct 15, 2002

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Org 36286 120 μg + Puregon® 150 IU On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.	Drug: Org 36286 Intra-abdominal injection of Org 36286 Other Names: Corifollitropin alpha Drug: Puregon® Subcutaneous Puregon® 150 IU Other Names: recFSH Drug: Orgalutran® Subcutaneous Orgalutran® 0.25 mg Other Names: ganirelix (Ganirelix Acetate Injection) Drug: Pregnyl® Subcutaneous Pregnyl® 10,000 IU Other Names: human chorionic gonadatropin hCG
Experimental: Org 36286 180 μg + Puregon® 150 IU Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.	Drug: Org 36286 Intra-abdominal injection of Org 36286 Other Names: Corifollitropin alpha Drug: Puregon® Subcutaneous Puregon® 150 IU Other Names: recFSH Drug: Orgalutran® Subcutaneous Orgalutran® 0.25 mg Other Names: ganirelix (Ganirelix Acetate Injection) Drug: Pregnyl® Subcutaneous Pregnyl® 10,000 IU Other Names: human chorionic gonadatropin hCG
Experimental: Org 36286 240 μg + Puregon® 150 IU Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.	Drug: Org 36286 Intra-abdominal injection of Org 36286 Other Names: Corifollitropin alpha Drug: Puregon® Subcutaneous Puregon® 150 IU Other Names: recFSH Drug: Orgalutran® Subcutaneous Orgalutran® 0.25 mg Other Names: ganirelix (Ganirelix Acetate Injection) Drug: Pregnyl® Subcutaneous Pregnyl® 10,000 IU Other Names: human chorionic gonadatropin hCG
Active Comparator: Puregon® 150 IU On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.	Drug: Puregon® Subcutaneous Puregon® 150 IU Other Names: recFSH Drug: Orgalutran® Subcutaneous Orgalutran® 0.25 mg Other Names: ganirelix (Ganirelix Acetate Injection) Drug: Pregnyl® Subcutaneous Pregnyl® 10,000 IU Other Names: human chorionic gonadatropin hCG

Outcome Measures

Primary Outcome Measures

Median Puregon® Dose (IU) Required To Reach Criteria for Administration of Human Chorionic Gonadotropin (hCG) For Induction of Final Oocyte Maturation [Day 8 Up to End of Menstrual Cycle]

Secondary Outcome Measures

Number of Participants Experiencing Cancellation of Menstrual Cycle [Up to End of Menstrual Cycle]
Number of Cumulus-Oocyte-Complexes Experienced By Participants During One Menstrual Cycle [Up to End of Menstrual Cycle]
Number of Good Quality Embryos Obtained [Up to One Menstrual Cycle]
Number of Participants With Ongoing Pregnancies [Up to 10 Weeks Following hCG Administration]
Number of Participants With Anti-Org 36286 Antibodies [Up to 2 Weeks Following Embryo Transfer]
Number of Participants With Abnormal Laboratory Findings [Up to 2 Weeks Following Embryo Transfer]
Number of Participants With Abnormal Vital Signs [Up to 2 Weeks Following Embryo Transfer]
Number of Participants With Serious Adverse Events (SAEs) [Up to 2 Weeks Following Embryo Transfer]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 39 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Females of couples with an indication for COH and IVF or IVF/ICSI;
Body mass index (BMI) >=18 and <=29 kg/m^2;
Normal menstrual cycle length: 24-35 days;
Ejaculatory sperm;

Exclusion Criteria:

History of/or current endocrine abnormality such as polycystic ovary syndrome (PCOS), or polycystic ovaries according to ultrasound scan (USS), (treated) hyperprolactinemia or evidence of ovarian dysfunction;
More than three unsuccessful COH cycles for IVF since the last established ongoing pregnancy (if applicable);
History of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment;
Any clinically relevant hormone value outside the reference range during the early follicular phase (menstrual Cycle Day 2-7) as measured by the local laboratory (FSH, luteinizing hormone [LH], estradiol [E2], progesterone [P], total testosterone [T], thyroid stimulating hormone [TSH], and prolactin);
Any clinically relevant abnormal laboratory value;
Any ovarian and/or abdominal abnormality interfering with ultrasound examination;
Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);
Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease;
History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;
Hypersensitivity to Orgalutran® or any of its components;
Administration of investigational drugs within three months prior to screening.
Use of hormonal preparations within one month prior to the start of Org 36286 with the exception of thyroid medication.